{Reference Type}: Journal Article
{Title}: Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: A prospective cohort study.
{Author}: Ding L;Guan L;Li X;Xu X;Zou Y;He C;Hu Y;Wan J;Huang X;Lei Y;He W;Xia L;Xiong H;Luo L;Lu N;Zhu Y;
{Journal}: J Clin Lipidol
{Volume}: 17
{Issue}: 1
{Year}: Jan-Feb 2023
{Factor}: 5.365
{DOI}: 10.1016/j.jacl.2022.11.006
{Abstract}: Data on recurrent hypertriglyceridemia-induced acute pancreatitis (HTG-AP) are scarce.<BR>To investigate the incidence and risk factors for recurrence of HTG-AP, and the effect of triglyceride (TG) lowering drugs post index attack on recurrence.<BR>This study was a prospective cohort study of adult patients with first episode of HTG-AP from December 2019 to February 2021 who were followed until recurrence or death, or February 2022. The cumulative incidence function and Fine and Gray's competing-risk model were applied to the analyses.<BR>A total of 317 patients were enrolled, and the 12-month and 18-month cumulative recurrence incidences were 8% and 22%, respectively. The cumulative recurrence incidence was 2 times higher in patients whose serum TG levels post index attack were ≥5.65 mmol/L (subdistribution hazard ratio [SHR], 2.00; 95% confidence interval [CI], 1.05-3.80; P = 0.034) compared to patients with TG <5.65 mmol/L. The recurrence rate was 3.3 times higher in patients whose glucose levels post index attack were ≥7.0 mmol/L (SHR, 3.31; 95% CI, 1.56-7.03; P = 0.002) than in patients with glucose <7.0 mmol/L). Compared to TG lowering drugs for less than 1 month post index attack, treatment for longer than 12 months decreased the incidence of recurrence by 75% (SHR, 0.25; 95% CI, 0.08-0.80; P = 0.019).<BR>The HTG-AP recurrence incidence is high and closely associated with high levels of TGs and glucose post index attack. Long-term TG lowering drugs treatment significantly decreases this recurrence.